Heidelberg Engineering GmbH   Report issue

For profit Phase 2
Founded: Heidelberg Germany (1991)
Status: No NME R&D (1991)

Organization Overview

First Clinical Trial
2019
NCT03959592
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Heidelberg Engineering GmbH

Active Ingredients

Drugs in Phase 2 Trials (3)

lutein (1 trial)

mesozeaxanthin (1 trial)

zeaxanthin (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Glaucoma (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 3